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Abstract
Background: Urinary bladder cancer is often a result of exposure to chemical carcinogens such as cigarette smoking.
Because of histological similarity, chemically-induced rodent cancer model was largely used for human bladder cancer
studies. Previous investigations have suggested that nicotinamide, water-soluble vitamin B3, may play a key role in cancer
prevention through its activities in cellular repair. However, to date, evidence towards identifying the genetic alterations of
nicotinamide in cancer prevention has not been provided. Here, we search for the molecular signatures of cancer
prevention by nicotinamide using a N-butyl-N-(4-hydroxybutyl)-nitrosamine (BBN)-induced urinary bladder cancer model in
mice.
Methodology/Principal Findings: Via microarray gene expression profiling of 20 mice and 233 human bladder samples, we
performed various statistical analyses and immunohistochemical staining for validation. The expression patterns of 893
genes associated with nicotinamide activity in cancer prevention were identified by microarray data analysis. Gene network
analyses of these 893 genes revealed that the Myc and its associated genes may be the most important regulator of bladder
cancer prevention, and the gene expression signature correlated well with protein expression data. Comparison of gene
expression between human and mouse revealed that BBN-induced mouse bladder cancers exhibited gene expression
profiles that were more similar to those of invasive human bladder cancers than to those of non-invasive human bladder
cancers.
Conclusions/Significance: This study demonstrates that nicotinamide plays an important role as a chemo-preventive and
therapeutic agent in bladder cancer through the regulation of the Myc oncogenic signature. Nicotinamide may represent a
promising therapeutic modality in patients with muscle-invasive bladder cancer.
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Introduction
Many bladder cancers can be linked to chemical carcinogens,
and in western populations approximately one-third to one-half of
bladder cancers are associated with cigarette smoking [1,2].
Although the causative substance in cigarette smoke has not yet
been identified, a- and b-naphthylamine are suspected agents. As
putative carcinogens for bladder cancer, aromatic amines such as
b-naphthylamine, 4-aminobiphenyl, benzidine, and 2-amino-1-
naphthol may account for up to 20 to 30% of bladder cancer cases
[3,4]. There are two primary chemically-induced models of
urinary bladder cancer in rodents, which are induced by
administration of N-butyl-N-(4-hydroxybutyl)-nitrosamine (BBN)
in either mice or rats [5,6]. The resultant tumors are histologically
similar to the human disease, and are manifested via two different
carcinogenic pathways; namely, non-muscle-invasive bladder
cancer (NMIBC) in rats and muscle-invasive bladder cancer
(MIBC) in mice [7,8]. Because human bladder cancer is often a
result of exposure to chemical carcinogens, these rodent models
are useful for understanding human bladder cancer. Williams et al
illustrated the overall gene expression profiles of rodent tumors
and provided a list of genes that are likely candidates for driving
bladder cancer development and progression [9].
Nicotinic acid is a water-soluble vitamin belonging to the
vitamin B family. It is found in many animal and plant tissues, and
has antihyperlipidemic activity. In the body, nicotinic acid is
converted to its active form nicotinamide, which is a component of
the coenzymes nicotinamide adenine dinucleotide (NAD) and its
phosphate form, NADP. These coenzymes play an important role
in tissue respiration and in glycogen, lipid, amino acid, protein,
and purine metabolism. Current research suggests that nicotin-
amide, or vitamin B3, may play a key role in cancer prevention
PLoS ONE | www.plosone.org 1 October 2011 | Volume 6 | Issue 10 | e26131through its activities in cellular repair. Leading scientists studying
nicotinamide nutrition believe the vitamin shows promise for
treating and even preventing cancer. Myron et al demonstrated
that cells depleted of nicotinamide develop cancer ten times faster
than those receiving sufficient amounts of the vitamin [10]. Diet is
a major factor in the incidence of bladder cancer, with both
beneficial and detrimental components, and nicotinamide is one of
the beneficial components. Though the optimal dose of nicotin-
amide is still undetermined, nicotinamide is also a promising
adjunct to chemotherapy because of its relationship to tumor
necrosis (killing) factor, a relatively novel factor that selectively kills
cancer cells [11,12,13]. In the current study, we sought to identify
the genetic signatures of nicotinamide in cancer prevention using a
BBN-induced mouse bladder cancer model, and investigated the
potential efficacy of nicotinamide treatment in bladder cancer
patients.
Materials and Methods
Mouse tissue samples
Animal studies were done in accordance with the guidelines of
the Institutional Animal Care Committee of Chungbuk National
University (permit numbers: CBNUA-030-0901-02). Female
C3H/He mice were obtained from Japan SLC, Inc. (Shizuoka,
Japan) at 6 weeks of age and were housed in cages (five per cage).
The animals were kept in a lighted room for 12 hours each day,
maintained at 2362uC and 55%65% humidity. BBN was
obtained from Tokyo Kasei Kogyo Co. (Tokyo, Japan), and
nicotinamide was purchased from Sigma Chemical Co. (St. Louis,
MO). BBN was diluted with tap water to a final concentration of
0.05%. For analysis of the preventive effects of nicotinamide,
drinking water was supplemented with 0.1%, 0.25%, 0.5%, or 1%
nicotinamide with or without 0.05% BBN for 20 weeks. All mice
received the first treatment at 7 weeks of age, and were sacrificed
at 20 weeks after the first treatment. At necropsy, the urinary
bladders of mice were inflated with normal saline and then
removed, and under a high-intensity light were examined for gross
lesions. After inspection, all bladders were frozen for histopath-
ologic examination and subsequent molecular assays. A portion of
each tissue was fixed and processed for routine paraffin
embedding, cut into 5-mm sections, and mounted for hematoxylin
and eosin staining for histopathology. Bladder tumors were
classified into NMIBC and MIBC based on the extent of invasion
into the muscle.
RNA extraction, microarray experiments, and data
processing
Total RNA was isolated using TRIzol reagent (Life Technol-
ogies, NY), according to the manufacturer’s protocol. The quality
and integrity of the RNA were confirmed by agarose gel
electrophoresis and ethidium bromide staining, followed by visual
examination under ultraviolet light. Five-hundred nanograms of
total RNA were used for labeling and hybridization, according to
the manufacturer’s protocols (Illumina Mouse-6 BeadChips,
version 1.0). Arrays were scanned with an Illumina Bead Array
Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc.,
San Diego, CA) according to the manufacturer’s instructions.
After scanning, the microarray data were filtered by detection P-
value (P,0.05) which was provided by Genome Studio
TM
software (Illumina, Inc., San Diego, CA) and were normalized
using quantile normalization in the R language environment
(version 2.10.0, available at http://www.r-project.org/). Measured
gene expression values were log2 transformed and median-
centered across genes and samples. The full microarray data set
is available in the National Center for Biotechnology Information
(NCBI) Gene Expression Omnibus (GEO) public database under
the data series accession number GSE21636. All microarray data
is Minimum Information About a Microarray Experiment
(MIAME) compliant.
Human bladder cancer microarrays
For comparative analysis of mouse and human cancer, we used
a previously published data set of human bladder cancer
microarrays (Korean cohort), GSE13507, from the NCBI GEO
public database [14]. The data set consisted of 165 primary
bladder cancer samples (103 NMIBCs and 62 MIBCs), 58 samples
of histologically normal-looking surrounding tissues, and 10
normal bladder mucosae from patients with benign diseases.
These gene expression data were constructed on Illumina
HumanWG-6 BeadChips (version 2). For further validation, we
also used another human bladder cancer dataset (Spanish cohort,
Affymetrix U133A GeneChip), which consisted of 24 NMIBCs, 66
MIBCs, and 38 normal bladder mucosae [15].
Real time reverse transcriptase polymerase chain
reaction (RT-PCR)analysis
RT-PCR was performed using a Rotor Gene 6000 PCR system
(Corbett Research, Mortlake, Australia). RT-PCR reactions in
micro-reaction tubes (Corbett Research) contained primers and
SYBR Premix EX Taq (Takara Bio Inc., Otsu, Japan). Spectral
data were captured and analyzed using Rotor-Gene Real-Time
Analysis Software 6.0 Build 14 (Corbett Research). Gene
expression was normalized to Gapdh expression.
Immunohistochemical analysis
Immunohistochemical staining was performed on formalin-
fixed, paraffin-embedded specimens of mouse normal and tumor
bladders. Sections were incubated with the primary antibodies
anti-Myc (Santa Cruz Biotechnology Inc., Santa Cruz, CA) and
anti-Pmp22 (Abcam, UK). For automated staining, Benchmark
XT autostainer (Roche Diagnostics, Indianapolis, IN) was used.
After staining, we evaluated both the staining intensity and
proportion of stained epithelial cells. Staining intensity was
classified as follows: 1, weak; 2, moderate; and 3, strong. The
proportion of positive cells was expressed as a percentage of the
total number of epithelial cells examined, and assigned to one of
five categories: 0, ,5%; 1, 5–25%; 2, 26–50%; 3, 51–75%; and 4,
.75%. Scores for the percentage of positive cells and staining
intensity were multiplied together to produce the immunoreactiv-
ity score (IS) for each specimen. The IS of Myc and Pmp22 was
measured in the nucleus and cytoplasm, respectively. Each
specimen was examined and scored separately by three investiga-
tors, and discrepant scores were discussed until agreement was
reached.
Western blot analysis
After rinsing in distilled water, samples in glass tube containing
1 ml of cell lysis buffer were mechanically homogenized with a
tissue homogenizer. The homogenate was transferred to a 1.5 ml
tube and were centrifuged at 14,000 rpm for 5 minutes at 4uC.
The upper aqueous phase was discarded and mixed with 2ul of
phenylmethylsulfonyl fluoride and 200 ul of protein analysis
buffer. After incubation for 1 hour at 4uC, samples were
centrifuged at 14,000 rpm for 30 minutes at 4uC. The upper
aqueous phase was transferred to new tube and stored at 280uC
until use. Protein concentrations were determined by Bio-Rad
protein assay (Bio-Rad Laboratories, Hercules, CA). Each sample
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sulfate gel and transferred to polyvinylidene fluoride membrane
(GE Healthcare, San Antonio, TX). Western blots were analyzed
with antibodies against Pmp22 (abcam, Cambridge, UK) and Myc
(LifeSpan BioSciences, Seattle, WA).
Statistical analysis
To compare the molecular characteristics between different
mouse groups, we performed a hierarchical clustering analysis. A
hierarchical clustering algorithm, using the centered correlation
coefficient as the measure of similarity and average linkage
clustering, was applied as described in Eisen et al [16]. We
identified genes that were differentially expressed between two
groups using a random-variance two-sample t-test [17]. Genes
were considered to have statistically significant differences in
expression if the P-value was less than 0.001. We also performed a
global test of whether the expression profiles differed between the
classes by performing permutations. For each permutation, the P-
values were re-computed and the number of genes significant at
the 0.001 level was noted. The proportion of the permutations that
resulted in at least as many significant genes as the actual data was
taken as the significance level of the global test. While obtaining
differentially expression genes, we selected genes that had a 1.2
fold or more difference of mean expression values of two groups.
To explore the relationships between tumorigenic genes that
responded to nicotinamide, we examined functional associations
among the genes and generated gene networks based on whether
they had more interconnected genes than would be expected to
occur by chance. The significance of each network was estimated
using the scoring system provided by the Ingenuity Pathway
Analysis Tool (version 7.5). The scores were determined by the
number of differentially expressed genes within each of the
networks and the strength of the associations among the network
members.
As a means of comparing gene expression patterns between
human and mouse samples, the microarray data of mouse models
were pooled with the data set of human bladder cancers using
HomoloGene (NCBI), a system for detection of the homologues
genes in several eukaryotic genomes [18]. Before integration of
the two data sets, the expression levels of each gene in each data
set were standardized independently, to a mean of zero and a
standard deviation of 1. To predict mouse models against human
tissues, we applied four different prediction models: compound
covariate predictor [19], linear discriminator analysis [20],
nearest centroid classification [20], and support vector machines
[21]. The models incorporated genes that were differentially
expressed between the two classes using a two-sample t-test.
Genes were considered to have statistically significant differences
in expression if the P-value was less than 0.001. We estimated the
prediction error of each model using leave-one-out cross-
validation (LOOCV), as described by Simon et al [22]. For each
LOOCV training set, the entire model-building procedure was
repeated, including the gene selection process. Cross-species
prediction procedure was performed in BRB ArrayTools (version
3.8.0).
Results
The efficacy of nicotinamide as a protective agent
against BBN-induced mouse bladder cancers
To investigate the effect of nicotinamide on tumor formation in
the BBN-induced bladder cancer model, mice received 0.05%
BBN alone or BBN plus increasing concentrations of nicotinamide
in their drinking water for 20 weeks (Figure 1A). Notice-
ably, nicotinamide supplementation inhibited tumor formation.
Supplementation with 0.5% nicotinamide reduced the tumor
formation ratio from 100% to 74%, and 1% nicotinamide reduced
the ratio even further, to 52% (Figure 1B). Histological analysis of
bladder tumors from the various treatment groups revealed that
the development of MIBC was markedly inhibited by nicotin-
amide. Treatment with 0.1% nicotinamide reduced the incidence
of MIBC from 88 to 42%, and 1% nicotinamide reduced it even
further, to 12% (Figure 1B), which indicated that nicotinamide
strongly inhibits bladder tumor progression. Tumor volume was
also remarkably reduced by nicotinamide. Most of the BBN-
treated mice developed large tumors (average size, 129 mm
3).
Increasing the treatment of nicotinamide significantly reduced the
average tumor size (99 to 18 mm
3 when 0.1 to 1% nicotinamide
were treated, Figure 1C). These results demonstrated that
nicotinamide effectively prevents tumor formation and suppresses
tumor growth and progression to MIBC.
Differential gene expression patterns among
experimental groups
To characterize the gene expression patterns of nicotinamide in
cancer prevention, we randomly select 20 mouse bladders and
performed a gene expression profiling; five BBN-induced mouse
bladder tumors (MIBCs from Group G1, Figure 1A), five non-
tumor-bearing bladders treated with BBN and nicotinamide
(normal samples from Group G5, Figure 1A), five normal bladders
treated with 1% nicotinamide (Group G6 in Figure 1A), and five
normal bladders without treatment (Group G7 in Figure 1A). The
5 samples in each group were histologically identical each other.
We first applied hierarchical clustering analysis of gene expression
patterns to assess the molecular characteristics of the different
experimental groups. As expected, hierarchical clustering analysis
of gene expression data from all tissues yielded three major
clusters, one representing the normal bladder group, a second
representing the BBN-induced mouse bladder tumor group, and a
third representing the BBN + nicotinamide-treated non-tumori-
genic bladder group (Figure S1). Thus, gene expression patterns
reflecting the molecular configuration are readily distinguishable
between bladder tumors and non-tumor tissues.
We next aimed to identify gene sets that were differentially
expressed among the three different groups. Before analysis,
normal bladders treated with nicotinamide were excluded, since
there were no histopathologic or molecular differences between
normal and nicotinamide-treated bladder (Figure S1). We applied
Venn diagram comparison of two gene lists to select gene
expression patterns common to carcinogenesis and cancer
prevention. First, we generated two different gene lists by applying
the two-sample t-test (Figure 2A, P,0.001). Gene list A represents
the genes that were differentially expressed between the normal
bladder and BBN-induced tumor groups, and gene list B
represents the genes that were differentially expressed between
the BBN- and BBN + nicotinamide-treated groups. When
comparing the two gene lists, three different patterns were
observed: A not B (3,344 genes), A and B (893 genes), and B not
A (1,115 genes) (Figure 2B). Genes in the A not B category showed
BBN-induced tumor-specific expression patterns, while genes in
the B not A category displayed the expression patterns of genes
that responded to nicotinamide. Genes in the A and B category
exhibited both BBN-induced tumorigenic as well as nicotinamide-
responsive expression patterns. These results signified that 893
genes in the A and B category were common to both
carcinogenesis induced by BBN and to cancer prevention induced
by nicotinamide.
Genetic Changes by Nicotinamide in Bladder Cancer
PLoS ONE | www.plosone.org 3 October 2011 | Volume 6 | Issue 10 | e26131Biological insight to the gene expression patterns for
cancer prevention
To identify the predominant signaling networks active in the
prevention of bladder cancer by nicotinamide, gene network
analysis of the 893 genes in the cancer prevention signature
(Figure 2) was performed using Ingenuity
TM Pathways Analysis
software. Of the 893 genes, 477 were mapped to gene networks
defined by this tool. This analysis revealed a series of putative
networks and associated functional categories. The 10 putative
networks with the highest scores are listed in Table S1 and their
associated functions are illustrated in Figure S2.
As expected, genes involved in carcinogenesis-related functions
such as cellular growth and proliferation, cancer, cell death, and
DNA-replication and -repair were enriched, providing confidence
in our results. We also found that genes involved in inflammatory
response, cell-mediated immune response, infectious disease,
inflammatory disease, and immunological disease were also
present in significant numbers. Interestingly, a significant abun-
dance of genes involved in skeletal/muscular system development
and disorders was observed (Figure S2).
Examination of the enriched genes revealed several important
signaling networks (Table S1), the most striking of which showed
predominant activation of the Myc, one of the oncogenic
signatures (Figure 3). Myc formed the primary hub of the gene
network, with the highest connectivity to the rest of the genes in
the network, suggesting that Myc could be a critical molecular
factor in both carcinogenesis induced by BBN and cancer
prevention induced by nicotinamide. Many of the satellite genes
connected to Myc (i.e., MSH6 [Msh6], METAP2 [Metap2], LMNB1
[Lmnb1], HK2 [Hk2], PPAT [Ppat], PGK1 [Pgk1], CCT2 [Cct2], and
PMP22 [Pmp22]) (Figure 3) participate in tumorigenesis, cell
proliferation, cell growth, or apoptosis, which correspond to the
best-known activities of Myc. These findings strongly indicated that
oncogenic function of the Myc and its associated genes may be
regulated by nicotinamide treatment to prevent bladder carcino-
genesis.
Validation of the Myc signature for cancer prevention by
nicotinamide
To validate our newly identified gene expression signature for
cancer prevention by nicotinamide, we additionally carried out
gene expression and protein expression analyses. Among the genes
of the Myc signature identified by gene network analysis (Figure 3),
Myc as a primary hub oncogene and Pmp22 as a tumor-suppressed
Figure 1. Efficacy of nicotinamide (NC) against N-butyl-N-(4-hydroxybutyl)-nitrosamine (BBN)-induced tumors. (A) Experimental
protocol for analysis of the preventive effects of NC. Mice were treated with BBN alone or in combination with the indicated amounts of NC for 20
weeks. ‘‘n’’ indicates the number of mice in each group. A dose of 0.1% NC in drinking water is roughly equivalent to 100 mg/Kg/day. (B) Summary of
the incidence of tumor formation, non-muscle invasive bladder cancer (NMIBC), and muscle invasive bladder cancer (MIBC) for each treatment group.
The number above each bar indicates the number of mice in each histological category. (C) The box plot comparing tumor volumes of the treatment
groups. The P-values were obtained by two sample t-tests between group G1 and other groups.
doi:10.1371/journal.pone.0026131.g001
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validation, and the results are presented in Table 1 and Figure 4.
We first performed gene expression analysis by RT-PCR. The
expression levels of Myc in BBN-induced bladder cancer group were
significantly higher than normal or BBN + nicotinamide-treated
groups (P,0.001 and P=0.02 by two sample t-test respectively,
Figure 4, A). On the other hand, the expression levels of Pmp22 in
BBN-induced bladder cancer group were significantly decreased as
compared with normal or BBN + nicotinamide-treated groups
(P=0.02andP=0.03bytwosamplet-testrespectively,Figure4,B).
To determine whether gene expression signature we identified
agree with protein expression levels, immunohistochemical
analysis was carried out. We observed that Myc was highly
expressed in the cytoplasm of normal mouse urothelium cells, but
was not expressed in the nucleus. Myc was mainly localized to the
nucleus of the tumor cells in the BBN-induced mouse bladder
tumor. Both a nuclear and a cytoplasmic distribution of Myc was
observed; however, the number of Myc-positive nuclei in the
mouse urothelium treated with BBN and nicotinamide was
significantly lower than in the BBN-induced bladder tumor, and
the cytoplasmic staining intensity of Myc in either BBN group was
weaker than that in normal urothelium (Figure 4, C and Table 1).
We also found that Pmp22 was distributed in the cytoplasm of
normal mouse urothelium, whereas there was no evidence of
either cytoplasmic or nuclear expression of Pmp22 in the BBN-
induced mouse bladder tumor. In the BBN + nicotinamide-treated
urothelium, cytoplasmic Pmp22 expression was observed; howev-
er, the level of Pmp22 expression was reduced relative to that in
normal urothelium (Figure 4, D and Table 1).
We also performed western blots for Myc and Pmp22 to
rigorously verify our gene expression profiling analysis. On
western blot analysis, Myc was highly expressed in the BBN-
induced mouse bladder tumor group compared to normal and the
BBN + nicotinamide-treated non-tumorigenic bladder group, but
Myc expression did not show any difference between normal and
the BBN + nicotinamide-treated non-tumorigenic bladder group.
On the other hand, Pmp22 expression level in normal bladder
group was significantly higher than in the BBN-induced mouse
bladder tumor group. Although Pmp22 expression was observed
in the BBN + nicotinamide-treated non-tumorigenic bladder
group, the level of Pmp22 expression was reduced relative to that
in normal. These results indicated that the changes in the protein
expression levels of the Myc and its associated genes agreed well
with the changes in the gene expression levels revealed by
microarray analysis. The results also provided strong evidence for
the reliability of the gene expression signature identification.
Comparison of gene expression between human and
mouse bladder cancers
Given the three distinct subgroups of the mouse experimental
model, we examined how well these models recapitulate human
bladder cancer phenotypes as defined by gene expression patterns.
Because two different microarray platforms were used to study
mouse and human bladder cancer (Korean cohort), we selected
homologous genes that were present in both microarrays using
HomoloGene, which provided information on homologous mouse
and human genes. A total of 11,565 homologous genes were
present in both microarrays. In hierarchical clustering analysis of
the integrated data, the three subgroups were well separated from
each other (Figure 5). Except for only one mouse sample, the gene
expression patterns of the bladder in normal mice and BBN +
nicotinamide-treated mice were very similar to those of normal
mucosa or mucosa surrounding (adjacent to) cancers in human
(cluster I in Figure 5). In contrast, the expression patterns of mouse
bladder cancers from the BBN-induced tumor group were very
similar to those of MIBCs in humans (cluster III in Figure 5).
We next applied supervised learning methods to validate the
unsupervised cluster analysis. We applied four independent
prediction methods to determine which of the mouse models
Figure 2. Comparative analysis of differentially expressed
genes among the experimental groups. (A) Venn diagram of
genes selected by two-sample t-test in the mouse model. The purple
circle (gene list A) represents genes differentially expressed between
normal bladder tissues and N-butyl-N-(4-hydroxybutyl)-nitrosamine
(BBN)-induced bladder tumors. The blue circle (gene list B) represents
genes differentially expressed between BBN-induced bladder tumors
and BBN + nicotinamide (NC) treated non-tumor tissues. We applied a
cut-off P-value of less than 0.001 to select genes whose expression was
significantly different between the two groups. (B) Expression patterns
of selected genes in the Venn diagram. Among the genes in A not B
category, 1,525 genes (45.6%) showed up-down patterns and 1,819
genes (54.4%) showed down-up patterns in normal and BBN-induced
cancer. In the A and B category, 290 genes (32.5%) and 603 genes
(67.5%) represented down-up-down patterns and up-down-up pat-
terns, respectively, in normal, BBN-induced cancer, and BBN + NC-
treated bladder groups. In the B not A category, 606 genes (54.3%)
displayed down-up patterns and 509 genes (45.7%) exhibited up-down
patterns in BBN-induced cancer and BBN + NC-treated bladder groups.
The data are presented in matrix format in which rows represent
individual genes and columns represent each tissue. The red and green
colors reflect high and low expression levels, respectively.
doi:10.1371/journal.pone.0026131.g002
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expression data sets from the two subclasses of human bladders to
train prediction methods (Normal vs. MIBC, NMIBC vs. MIBC,
and Normal vs. NMIBC). All prediction methods predicted that
most normal and BBN + nicotinamide-treated mouse bladders are
relatively similar to normal mucosa or mucosa surrounding
(adjacent to) cancers in human, whereas BBN-induced mouse
bladder cancers are relatively similar to MIBC in human (Table 2).
In addition, when we applied prediction methods trained with
NMIBCs and MIBCs, we observed that all BBN-induced mouse
bladder cancers were predicted as MIBC (Table 2). Furthermore,
when applying prediction methods trained with normal and
NMIBCs, most BBN + nicotinamide-treated mouse bladders were
relatively similar to normal mucosa or mucosa surrounding
Figure 3. Gene networks enriched with genes modulated by nicotinamide in cancer prevention. Up- and down-regulated genes in the
mouse bladder cancers are indicated in red and green, respectively. The intensity of the color is indicative of the degree of over- or under-expression.
Genes without highlighted color are not part of the progression signature but are associated with the regulated genes. Each line and arrow
represents functional and physical interactions between the genes and the direction of regulation reported in the literature.
doi:10.1371/journal.pone.0026131.g003
Table 1. Protein expression levels of Myc and Pmp22 in the mouse model.
Experimental groups Nucleic Myc (mean ± SD) Cytoplasmic Myc (mean ± SD) Nucleic Pmp22 (mean ± SD) Cytoplasmic Pmp22 (mean ± SD)
Normal (n=5) 0.460.54 4.661.34 0.460.54 10.861.64
NC (n=5) 0.660.54 4.261.10 0.460.54 10.262.68
BBN (n=5) 11.461.34 2.061.22 0.260.45 0.860.44
BBN + NC (n=5) 2.262.28 3.261.09 0.660.55 9.263.89
The protein expression levels of Myc and Pmp22 were measured in the nucleus and cytoplasm. The P-values were obtained for the following categories: Normal vs.
N-butyl-N-(4-hydroxybutyl)-nitrosamine (BBN) (Nucleic Myc, P,0.001; Cytoplasmic Pmp22, P,0.001), BBN vs. BBN + nicotinamide (NC) (Nucleic Myc, P,0.001;
Cytoplasmic Pmp22, P=0.001), and Normal vs. BBN + NC (Nucleic Myc, P=0.12; Cytoplasmic Pmp22, P=0.42). The P-values were calculated by two sample t-tests to
each comparison. When applying correlation test between nucleic Myc and cytoplasmic Pmp22, two molecules were strongly inversely correlated. (r=20.83, P,0.001).
Correlation test was carried out by Pearson correlation test. SD indicates standard deviation.
doi:10.1371/journal.pone.0026131.t001
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significant gene lists of all comparisons (Normal vs. MIBC,
NMIBC vs. MIBC, and Normal vs. NMIBC) were described in
Table S3, S4, and S5, respectively. The biological implications of
these genes in each comparison were also illustrated in Figure S4,
S5, and S6, respectively. Consistent results were obtained when
comparing mouse and another human bladder cancer dataset
(Spanish cohort, Figure S3 and Table S2). Taken together, these
data indicate that chemically-induced mouse bladder cancer
models are very similar with human MIBCs and BBN +
nicotinamide-treated mouse bladders are very similar with normal
mucosa histologically and genetically, which supports the proposal
that nicotinamide treatment might have a potential efficacy as
chemo-preventive agent for MIBC development.
Discussion
In this study, we clearly demonstrated three different gene
expression patterns among normal bladder, BBN-induced bladder
tumor, and BBN + nicotinamide-treated non-tumorigenic bladder.
Based on the results of the gene network analysis, we identified a
putative molecular signature that might be responsible for bladder
Figure 4. Validation of the gene exression signature in the mouse models (Normal, N-butyl-N-(4-hydroxybutyl)-nitrosamine [BBN],
and BBN + nicotinamide [NC]). Real-time reverse transcriptase polymerase chain reaction (RT-PCR) analysis was performed for Myc (A) and Pmp22
(B). Differences (P values) between mouse groups were obtained by two-sample t-test. The y-axis indicates (expression ratio of each gene / Gapdh)
61000. Immunohistochemical analysis of Myc (C) and Pmp22 (D) was carried out to confirm protein expression levels. Detection of Myc (E) and
Pmp22 (F) protein expression was also determined by Western blot analysis.
doi:10.1371/journal.pone.0026131.g004
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signature was confirmed by immunohistochemical analysis. In
addition, through cross-species comparison of gene expression
patterns, we identified similarity between the mouse bladder
cancer model and human bladder cancer, which opens the gate to
examining the usefulness of nicotinamide treatment for human
bladder cancer.
The accumulated evidence from previous reports documenting
the association between nicotinamide and human cancer implies
that nicotinamide plays a key role in cancer prevention through its
activities in cellular repair [10,23,24]. Recent study of nicotin-
amide suggests that nicotinamide deficiency is strongly associated
with human cancers, and nicotinamide supplementation for cancer
patients decreases the severity of side effects of chemotherapy
[25,26]. Furthermore, it was reported more recently that nicotin-
amide treatment increased the efficacy of radiotherapy in locally
advanced bladder carcinoma [27]. However, to date, evidence
towards identifying the genetic alterations of nicotinamide in
cancer prevention has not been provided. Therefore, we investi-
gated a potential functional association between nicotinamide and
cancer prevention by performing gene expression profiling of a
chemically-treated mouse bladder tumor model.
On the basis of the success of previous genome-wide gene
expression profile studies in animal cancer models [9,28,29,30,31],
we characterized different gene expression patterns among normal
bladders, BBN-induced bladder cancers, and BBN + nicotin-
amide-treated non-tumorigenic bladders. We began by assessing
the molecular characteristics of the different experimental groups
via an unsupervised clustering analysis (Figure S1), and then
applied a Venn diagram approach (Figure 2) to identify gene sets
that were differentially expressed among the three mouse groups
(normal, BBN, and BBN + nicotinamide). These results indicated
that the gene expression pattern of each experimental group is
strongly correlated with its histological classification, and the gene
expression signature (893 genes in Figure 2) we identified presents
the molecular characteristics of bladder cancer prevention by
nicotinamide.
The identification of stable and reliable gene-to-gene relation-
ships is an essential step towards unraveling the interactions and
functional correlations between genes [32]. Therefore, we
performed gene network analysis to identify the association of
these 893 genes (Figure 2) with cancer prevention by nicotinamide.
Interestingly, the Myc and its associated genes were the most
important putative effectors of nicotinamide in preventing bladder
carcinogenesis (Figure 3). This finding was further supported by
immunohistochemical analysis, which showed that changes of
protein levels in the Myc network agreed well with the microarray
gene expression patterns (Table 1 and Figure 4). These data
underscore the functional association between the Myc signature
and nicotinamide activity in cancer prevention.
Figure 5. Unsupervised hierarchical clustering of mouse homologous genes with human cancers (Korean cohort). Genes with
expression values that had a standard deviation of at least 0.9 were selected for hierarchical analysis (1,059 gene features). The red and green colors
reflect high and low expression levels, respectively. BBN, NC, NMIBC, and MIBC indicate N-butyl-N-(4-hydroxybutyl)-nitrosamine, nicotinamide, non-
muscle invasive bladder cancer, and muscle invasive bladder cancer, respectively.
doi:10.1371/journal.pone.0026131.g005
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context of gene networks, we identified a series of putative
networks and functional categories associated with nicotinamide
activity in cancer prevention (Table S1 and Figure S2). This
functional enrichment test revealed that nicotinamide actively
influences cell growth, cell proliferation, cancer, and the cell
cycle, which are the well-known characteristics of Myc.B e c a u s e
Myc is an independent predictor of bladder cancer progression
and an important gene in the bladder cancer signaling pathway
[33,34], the results strongly support the potential involvement of
Myc in the prevention of bladder cancer by nicotinamide. It was
reported previously that nicotinamide could epigenetically
stabilize RUNX3, one of the important tumor suppressors [35].
Interestingly, another study demonstrated that transcriptional
activity of the MYC promoter was down-regulated by up-
regulation of RUNX3 in colorectal cancer cells [36]. Moreover,
RUNX3 is a direct binding partner of histone deacetylase 2
(HDAC2) [37], transcriptional up-regluation of which promotes
Myc-induced oncogeneic effects [38]. Thus, we putatively suggest
that nicotinamide treatment may be effective in decreasing the
risk of bladder cancer progression by regulation of Myc which is
modulated by epigenetic alteration of Runx3, although further
experimental validation is needed.
The comparison of evolutionarily-conserved genes across
different species has been frequently used to infer the function
or evolutionary origin of a gene or protein. Cross-species
comparative profiling of the tumor-related expression patterns of
homologous genes has been applied in several human cancer
studies including those examining liver cancer [29,31,39], lung
cancer [40], breast cancer [41], and bladder cancer [9]. In the
current study, we investigated the potential value of nicotinamide
in the prevention of human cancer based on comparative analysis
of global expression patterns of homologous genes in human and
mouse bladder cancer. When compared with human gene
expression patterns, those of BBN-induced mouse bladder cancers
were more similar to those of invasive than non-invasive human
cancers, and those of the BBN + nicotinamide-treated group were
most similar to normal tissues in humans (Figure 5 and Table 2).
These results not only illustrated a strong correlation between
human and mouse gene expression patterns, but also demonstrat-
ed the potential utility of nicotinamide as a cancer preventive
agent for MIBC. It was further supported by a recent report that
radiotherapy with nicotinamide treatment significantly reduced
the risk of disease progression and death of MIBC [27].
Our results based on gene expression profiling of a mouse
bladder cancer model demonstrate that nicotinamide may be a
Table 2. Outcomes of the gene expression-based prediction methods (Korean cohort).
CCP LDA NEC SVM
Predicted subclass NORMAL MIBC NORMAL MIBC NORMAL MIBC NORMAL MIBC
Human samples
NORMAL (n=68) 58 10 57 11 58 10 57 11
MIBC (n=63) 14 49 14 49 14 49 12 51
Percentage correctly classified* 81.7 80.9 81.7 82.4
Mouse samples
NORMAL (n=5) 5 0 5 0 5 0 4 1
B B N ( n = 5 ) 0 50 50 51 4
BBN + N C ( n = 5 ) 3 23 23 24 1
Percentage correctly classified
{ 86.7 86.7 86.7 80
Predicted subclass NMIBC MIBC NMIBC MIBC NMIBC MIBC NMIBC MIBC
Human samples
NMIBC (n=102) 82 20 82 20 82 20 72 30
MIBC (n=63) 17 46 17 46 17 46 28 35
Percentage correctly classified* 77.5 77.5 77.5 64.8
Mouse samples
B B N ( n = 5 ) 0 50 50 50 5
Percentage correctly classified
{ 100 100 100 100
Predicted subclass NORMAL NMIBC NORMAL NMIBC NORMAL NMIBC NORMAL NMIBC
Human samples
NORMAL (n=68) 59 9 59 9 60 8 60 8
NMIBC (n=102) 5 97 5 97 5 97 7 95
Percentage correctly classified* 91.8 91.8 92.4 91.2
Mouse samples
BBN + N C ( n = 5 ) 4 14 14 13 2
Percentage correctly classified
{ 80 80 80 60
*Percentage for correct prediction during leave-one-out cross-validation.
{Percentage for histopathologically correct prediction of mouse tissues.
Abbreviations: CCP, compound covariate predictor; LDA, linear discriminator analysis; NEC, nearest centroid; SVM, support vector machines; NMIBC, non-muscle invasive
bladder cancer; MIBC, muscle invasive bladder cancer; BBN, N-butyl-N-(4-hydroxybutyl)-nitrosamine; NC, nicotinamide.
doi:10.1371/journal.pone.0026131.t002
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its associated genes. The use of nicotinamide could be a potentially
valuable chemo-preventive and therapeutic approach for preven-
tion of bladder cancer, and may improve the effectiveness of
currently available treatments.
Supporting Information
Figure S1 Gene expression patterns of the mouse
bladder cancer model. Genes were selected when at least 5
samples have detection P-value less than 0.05 at each probe. The
detection P-value was provided by Genome Studio
TM software
from Illumina, Inc. A total of 28,253 probes (21,611 genes) were
selected in this analysis. After filtering of probes, the data were
normalized by quantile normalization method, log2-transformed,
and median-centered across genes and samples. Finally, probes
with expression values that had a standard deviation of at least 0.5
were selected. A total of 6,659 probes (5,643 genes) were selected
in the cluster analysis. The red and green colors reflect high and
low expression levels, respectively. BBN indicates N-butyl-N-(4-
hydroxybutyl)-nitrosamine.
(TIF)
Figure S2 Functional classification of the genes modu-
lated by nicotinamide in cancer prevention. Classification
enrichment was determined using Ingenuity Pathway Analysis
software. The threshold of significance was -log (P=0.05).
(TIF)
Figure S3 Unsupervised hierarchical clustering of
mouse homologous genes with human cancers (Spanish
cohort). Genes with expression values that had a standard
deviation of at least 0.9 were selected for hierarchical analysis
(1,414 gene features). The red and green colors reflect high and
low expression levels, respectively. BBN indicates N-butyl-N-(4-
hydroxybutyl)-nitrosamine.
(TIF)
Figure S4 Functional classification of the significant
genes applied to gene expression-based prediction
methods (Comparison between normal and MIBC in
human). Top 20 highly scored biological functions were
illustrated. Genes involved in carcinogenesis-related functions
such as cancer, cell growth & proliferation, cell death, and DNA-
replication and -repair were enriched. Genes involved in immune
cell trafficking, inflammatory response, and immunological disease
were also present in significant numbers, consistent with function
enrichment test of mouse data (Figure S3). Classification
enrichment was determined using Ingenuity Pathway Analysis
software. The threshold of significance was 2log (P=0.05).
(TIF)
Figure S5 Functional classification of the significant
genes applied to gene expression-based prediction
methods (Comparison between NMIBC and MIBC in
human). Top 20 highly scored biological functions were
illustrated. It is found that genes involved in carcinogenesis-related
functions such as cancer, cell growth & proliferation, cell cycle
were enriched. Interestingly, genes involved in renal and
urological system development were also significantly enriched.
Classification enrichment was determined using Ingenuity Path-
way Analysis software. The threshold of significance was 2log
(P=0.05).
(TIF)
Figure S6 Functional classification of the significant
genes applied to gene expression-based prediction
methods (Comparison between normal and NMIBC in
human). Top 20 highly scored biological functions were
illustrated. Genes involved in carcinogenesis-related functions
such as cancer, cell growth & proliferation, cell death, and DNA-
replication and -repair were enriched. Genes involved in immune-
or inflammation-associated functions such as immune cell
trafficking, inflammatory response, immunological disease, and
inflammatory disease were also present in significant numbers.
Classification enrichment was determined using Ingenuity Path-
way Analysis software. The threshold of significance was 2log
(P=0.05).
(TIF)
Table S1 Top 10 list of gene networks from Ingenuity
TM
Pathway Analysis.
(DOC)
Table S2 Outcomes of the gene expression-based
prediction methods (Spanish cohort).
(DOC)
Table S3 Significant gene list (510 genes) applied to
gene expression-based prediction methods (Comparison
between Normal and MIBC in human).
(DOC)
Table S4 Significant gene list (417 genes) applied to
gene expression-based prediction methods (Comparison
between NMIBC and MIBC in human).
(DOC)
Table S5 Significant gene list (623 genes) applied to
gene expression-based prediction methods (Comparison
between Normal and NMIBC in human).
(DOC)
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